AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8479036 — intervention group
Group type: COMPARATOR
Intervention: Artery-ligated group
Number of subjects: 34
Study 3541963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotrin (2.5 mg/kg)
Number of subjects: 30
Study 3541963 — intervention group
Group type: COMPARATOR
Intervention: Isoptin
Number of subjects: 30
Study 31914685 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training (aerobic exercise or combination of aerobic exercise and resistance training)
Number of subjects: 16
Study 31914685 — intervention group
Group type: COMPARATOR
Intervention: NDD-CKD
Number of subjects: 16
Study 31914685 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 16
Study 30556713 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 270
Study 30556713 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 270
Study 30556713 — intervention group
Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 270
Study 27977757 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus vitamin D (500 mg DHA and 800 IU vitamin D daily)
Number of subjects: 41
Study 23930984 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal zinc plus vitamin A supplementation (VAZ)
Number of subjects: 0
Study 23930984 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alone (VA)
Number of subjects: 0
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were white
Number of subjects: 784
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients administered a selective serotonin reuptake inhibitor
Number of subjects: 784
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients administered two antipsychotic agents
Number of subjects: 784
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients administered an opiate
Number of subjects: 784
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients administered a diuretic non-antihypertensive agent
Number of subjects: 784
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based wheelchair use
Number of subjects: 784
Study 23002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients designated as 'high' fall risk
Number of subjects: 784
Study 19969286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 73
Study 19969286 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 73
Study 19969286 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 73
Study 19080398 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic Threshold (AT) group
Number of subjects: 54
Study 19080398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) group
Number of subjects: 54
Study 15942629 — intervention group
Group type: EXPERIMENTAL
Intervention: ILF (irinotecan plus high-dose 5-fluorouracil and leucovorin)
Number of subjects: 114
Study 15942629 — intervention group
Group type: COMPARATOR
Intervention: ELF (etoposide plus 5-fluorouracil and leucovorin)
Number of subjects: 114
Study 9164899 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training in patients with normal left ventricular (LV) function
Number of subjects: 20
Study 9164899 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training in patients with depressed left ventricular (LV) function
Number of subjects: 20
Study 10362612 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms/kg rhGH
Number of subjects: 21
Study 10362612 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 micrograms/kg rhGH
Number of subjects: 21
Study 10362612 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of rhGH (10.0 and 20.0 micrograms/kg)
Number of subjects: 21
Study 10362612 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 micrograms/kg rhGH
Number of subjects: 21
Study 7566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (nitroglycerin, calcium channel blocker or both)
Number of subjects: 64
Study 7566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 64
Study 7566950 — intervention group
Group type: EXPERIMENTAL
Intervention: Transduodenal sphincterotomy
Number of subjects: 64
Study 1982983 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BCH 069 by intravenous injection for 6 weeks 3 times weekly
Number of subjects: 3
Study 1982983 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BCH 069 by subcutaneous injection for 4 weeks 3 times weekly
Number of subjects: 3
Study 1982983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 7000249 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy irrigation
Number of subjects: 30
Study 7000249 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous action
Number of subjects: 30
Study 29538666 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood obesity risk information plus a personalized family history‐based risk estimate for their child
Number of subjects: 221
Study 29538666 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood obesity risk information
Number of subjects: 221
Study 29538666 — intervention group
Group type: COMPARATOR
Intervention: Control information
Number of subjects: 221
Study 26889993 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty using artificial cervical disks
Number of subjects: 30
Study 26889993 — intervention group
Group type: COMPARATOR
Intervention: Arthrodesis using zero‐profile devices
Number of subjects: 30
Study 24368867 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Demand Oxygen Delivery (SDOD)
Number of subjects: 10
Study 24368867 — intervention group
Group type: COMPARATOR
Intervention: Continuous Flow Oxygen (CFO)
Number of subjects: 10
Study 22242712 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate (MAL)‐PDT
Number of subjects: 8
Study 20227123 — intervention group
Group type: EXPERIMENTAL
Intervention: 68-Gy radiotherapy
Number of subjects: 664
Study 20227123 — intervention group
Group type: EXPERIMENTAL
Intervention: 78-Gy radiotherapy
Number of subjects: 664
Study 20227123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation based on PSA-level groupings
Number of subjects: 664
Study 20227123 — intervention group
Group type: COMPARATOR
Intervention: High-dose radiotherapy
Number of subjects: 664
Study 17513327 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 0.2 mg/kg per day (ACE-I)
Number of subjects: 66
Study 17513327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15727682 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (25 g protein and 60 mg isoflavones)
Number of subjects: 87
Study 15727682 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecified control foods)
Number of subjects: 87
Study 15727682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both soy and control groups
Number of subjects: 87
Study 11901278 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic-based treatment
Number of subjects: 4718
Study 11901278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4718
Study 11901278 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted follow-up scores based on baseline data
Number of subjects: 4718
Study 11901278 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data adjustment
Number of subjects: 4718
Study 9843546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI potato (HGI trial)
Number of subjects: 6
Study 9843546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI pasta (LGI trial)
Number of subjects: 6
Study 9843546 — intervention group
Group type: COMPARATOR
Intervention: Low-energy jelly (Con trial)
Number of subjects: 6
Study 7515999 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (35‐50 mg, n = 10)
Number of subjects: 20
Study 7515999 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (25 mg, n = 10)
Number of subjects: 20
Study 2648447 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy (psychoanalytically oriented)
Number of subjects: 70
Study 2648447 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (an antidepressant)
Number of subjects: 70
Study 2648447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (a benzodiazepine)
Number of subjects: 70
Study 2648447 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine (a methyl donor with antidepressive properties)
Number of subjects: 70
Study 2648447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29976474 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone nursing
Number of subjects: 0
Study 29976474 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone nursing recommendation (highest level of care)
Number of subjects: 0
Study 29976474 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone nursing recommendation (self-care)
Number of subjects: 0
Study 29976474 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance to nurse's recommendation
Number of subjects: 0
Study 27603398 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin orally administered 2 hours before surgery
Number of subjects: 44
Study 27603398 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally administered 2 hours before surgery
Number of subjects: 44
Study 24687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 30 mg (base)
Number of subjects: 16
Study 24687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg (base)
Number of subjects: 16
Study 24687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of primaquine and chloroquine
Number of subjects: 16
Study 24687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with primaquine
Number of subjects: 16
Study 22676397 — intervention group
Group type: COMPARATOR
Intervention: Preladenant (5-200 mg single doses)
Number of subjects: 108
Study 22676397 — intervention group
Group type: COMPARATOR
Intervention: Preladenant (10-200 mg once daily for 10 days)
Number of subjects: 108
Study 22676397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 20711565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz SSVEP
Number of subjects: 0
Study 20711565 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-Hz SSVEP
Number of subjects: 0
Study 20711565 — intervention group
Group type: COMPARATOR
Intervention: 12-Hz competing stimulus
Number of subjects: 0
Study 20711565 — intervention group
Group type: COMPARATOR
Intervention: 60-Hz competing stimulus
Number of subjects: 0
Study 18346973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Problem Solving Interview (DPSI) for caregivers
Number of subjects: 223
Study 18346973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Problem Solving Interview (DPSI) for youths
Number of subjects: 223
Study 16385906 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment A
Number of subjects: 0
Study 16385906 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy treatment B
Number of subjects: 0
Study 12585165 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin 500 mg once a day for 3 weeks
Number of subjects: 76
Study 12585165 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 76
Study 9105229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015-0.32 g/kg 5% rHb1.1 (n = 34)
Number of subjects: 48
Study 9105229 — intervention group
Group type: COMPARATOR
Intervention: 5% human serum albumin (HSA; n = 14)
Number of subjects: 48
Study 2029982 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava Extract WS 1490 (3 X 100 mg/day)
Number of subjects: 20
Study 2029982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7195257 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (EMBAY 8440, Biltricide)
Number of subjects: 153
Study 31640092 — intervention group
Group type: EXPERIMENTAL
Intervention: LIBRA index
Number of subjects: 308
Study 31640092 — intervention group
Group type: EXPERIMENTAL
Intervention: LIBRA-2
Number of subjects: 308
Study 28420440 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT treatment
Number of subjects: 18
Study 28420440 — intervention group
Group type: COMPARATOR
Intervention: Insulin-only treatment
Number of subjects: 18
Study 25403881 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic duct blockage (EDB)
Number of subjects: 57
Study 25403881 — intervention group
Group type: COMPARATOR
Intervention: Endolymphatic sac decompression (ESD)
Number of subjects: 57
Study 25000742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-designed mobile health education application on Pap testing
Number of subjects: 0
Study 25000742 — intervention group
Group type: COMPARATOR
Intervention: Standard pamphlet on Pap testing
Number of subjects: 0
Study 22976507 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 90
Study 22976507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 19273451 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 235
Study 19273451 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 2 mg/kg
Number of subjects: 235
Study 19273451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 18086061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermicol-P35
Number of subjects: 149
Study 18086061 — intervention group
Group type: COMPARATOR
Intervention: Non-animal-stabilized hyaluronic acid (NASHA)
Number of subjects: 149
Study 15303783 — intervention group
Group type: EXPERIMENTAL
Intervention: Desonide (cream, ointment, or lotion formulation)
Number of subjects: 0
Study 15303783 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 11718681 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 196
Study 11718681 — intervention group
Group type: COMPARATOR
Intervention: CETP concentration
Number of subjects: 196
Study 10553820 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 40 ppm
Number of subjects: 14
Study 10553820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 0.1 microg x kg(‐1) min(‐1)
Number of subjects: 14
Study 10553820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 3 to 5 microg x kg(‐1) min(‐1)
Number of subjects: 14
Study 10553820 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 14
Study 7872445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 2 g/day for adults and 50 mg/kg/day for children, intravenously once a day for three days
Number of subjects: 46
Study 7872445 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol, 60 mg/kg/day orally four times a day until defervescence, followed by 40 mg/kg/day for a total of 14 days
Number of subjects: 46
Study 7872445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 46
Study 7872445 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 46
Study 7872445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Chloramphenicol
Number of subjects: 46
Study 1982289 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal‐therapist‐involvement stress inoculation training
Number of subjects: 0
Study 1982289 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous changes in heart rate and report of anxiety during exposure
Number of subjects: 0
Study 1982289 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary plane flights in the two months following treatment
Number of subjects: 0
Study 1982289 — intervention group
Group type: COMPARATOR
Intervention: Flight avoiders
Number of subjects: 0
Study 642973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemolytic-uremic syndrome patients with endotoxemia
Number of subjects: 241
Study 642973 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated shigellosis
Number of subjects: 241
Study 642973 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes
Number of subjects: 241
Study 31945738 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback with a laser sensor (VFLS)
Number of subjects: 19
Study 31945738 — intervention group
Group type: COMPARATOR
Intervention: Control set
Number of subjects: 19
Study 31451913 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g daily + 1000 mg calcium + 800 IU vitamin D (strontium group; SG)
Number of subjects: 52
Study 31451913 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg calcium + 800 IU vitamin D (placebo group; PG)
Number of subjects: 52
Study 28859708 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA olfactory training
Number of subjects: 81
Study 28859708 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil olfactory training
Number of subjects: 81
Study 25959549 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) for BED
Number of subjects: 189
Study 24147266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin continued (Group 1)
Number of subjects: 150
Study 24147266 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin stopped (Group 2)
Number of subjects: 150
Study 24147266 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (Group 3 - Control)
Number of subjects: 150
Study 21486862 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab re-treated patients (n=112)
Number of subjects: 175
Study 21486862 — intervention group
Group type: COMPARATOR
Intervention: No rituximab second line (n=53)
Number of subjects: 175
Study 21486862 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 175
Study 21486862 — intervention group
Group type: COMPARATOR
Intervention: No autologous stem cell transplantation
Number of subjects: 175
Study 21319007 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 2.5 mg/day
Number of subjects: 34
Study 21319007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estriol (E3) 2 mg/day
Number of subjects: 34
Study 17245174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (5 mg/kg)
Number of subjects: 21
Study 17245174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15767960 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve placement
Number of subjects: 270
Study 15767960 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 270
Study 11575894 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 20
Study 11575894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20
Study 10197141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg, twice the daily recommended dose)
Number of subjects: 45
Study 10197141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9223914 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (3 x 10(6) U recombinant IFN alpha, subcutaneously three times a week, every other day, for a total of 12 doses)
Number of subjects: 5
Study 2506965 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 1020
Study 2506965 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 1020
Study 1203699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic glucose, fructose, and sorbitol solutions (IV)
Number of subjects: 28
Study 1203699 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 28
Study 31838497 — intervention group
Group type: EXPERIMENTAL
Intervention: TE (0.1 mg/day) + IMP (200 mg/day for 12 days)
Number of subjects: 172
Study 31838497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 31173128 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Admission (BA)
Number of subjects: 125
Study 31173128 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 125
Study 29319063 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Toothbrushing (STB) in Ultra-Conservative Treatment (UCT)
Number of subjects: 273
Study 29319063 — intervention group
Group type: COMPARATOR
Intervention: Conventional Restorative Treatment (CRT) with Unsupervised Toothbrushing (USTB)
Number of subjects: 273
Study 29319063 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART) with Unsupervised Toothbrushing (USTB)
Number of subjects: 273
Study 29319063 — intervention group
Group type: COMPARATOR
Intervention: No-treatment with Unsupervised Toothbrushing (USTB)
Number of subjects: 273
Study 25310510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lungs from heavy alcohol users
Number of subjects: 74
Study 25310510 — intervention group
Group type: COMPARATOR
Intervention: Lungs from lighter alcohol users
Number of subjects: 74
Study 22612560 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning intervention (associating thin-ideal models with synonyms of fake)
Number of subjects: 105
Study 22612560 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning intervention
Number of subjects: 105
Study 22612560 — intervention group
Group type: COMPARATOR
Intervention: Control condition (equivalent task without learning association)
Number of subjects: 105
Study 22187767 — intervention group
Group type: EXPERIMENTAL
Intervention: palanosetron (0.25 mg) IV
Number of subjects: 75
Study 22187767 — intervention group
Group type: COMPARATOR
Intervention: granisetron (3.0 mg) IV
Number of subjects: 75
Study 22187767 — intervention group
Group type: COMPARATOR
Intervention: ondansetron (8.0 mg) IV
Number of subjects: 75
Study 19332185 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 20000
Study 19332185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 20000
Study 19332185 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 20000